Trevi Therapeutics, Inc. Payments to Acquire Marketable Securities
Trevi Therapeutics, Inc. (TRVI) reported Payments to Acquire Marketable Securities of $162.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- Trevi Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $153.56M, a 797.51% increase year-over-year.
- Trevi Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $8.48M, a 69.20% decline year-over-year.
- Trevi Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $54.40M, a 20.37% increase year-over-year.
- Trevi Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $71.61M, a 448.78% increase year-over-year.
- Trevi Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $170.66M, a 73.33% increase from fiscal 2024.
- Trevi Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $98.46M, a 891.37% increase from fiscal 2023.
- Trevi Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $9.93M, a 92.13% decline from fiscal 2022.
- Trevi Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $126.22M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $153.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $162.05M 10-Q · filed 2026-08-06 | $216.44M derived: sum of 3 quarters · filed 2026-08-06 | $288.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $8.48M 10-Q · filed 2026-05-05 | $62.88M derived: sum of 2 quarters · filed 2026-05-05 | $134.49M derived: sum of 3 quarters · filed 2026-05-05 | $151.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $54.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $126.01M derived: sum of 2 quarters · filed 2026-03-17 | $143.12M derived: sum of 3 quarters · filed 2026-08-06 | $170.66M 10-K · filed 2026-03-17 |
| 2025-09-30 | $71.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $88.72M derived: sum of 2 quarters · filed 2026-08-06 | $116.27M 10-Q · filed 2025-11-13 | $161.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $17.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $44.66M 10-Q · filed 2026-08-06 | $89.85M derived: sum of 3 quarters · filed 2026-08-06 | $102.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $27.55M 10-Q · filed 2026-05-05 | $72.74M derived: sum of 2 quarters · filed 2026-05-05 | $85.79M derived: sum of 3 quarters · filed 2026-05-05 | $95.75M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $45.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $58.24M derived: sum of 2 quarters · filed 2026-03-17 | $68.20M derived: sum of 3 quarters · filed 2026-03-17 | $98.46M 10-K · filed 2026-03-17 |
| 2024-09-30 | $13.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $23.01M derived: sum of 2 quarters · filed 2025-11-13 | $53.27M 10-Q · filed 2025-11-13 | $54.22M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $9.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $40.22M 10-Q · filed 2025-08-07 | $41.17M derived: sum of 3 quarters · filed 2025-08-07 | $41.17M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $30.26M 10-Q · filed 2025-05-08 | $31.21M derived: sum of 2 quarters · filed 2025-05-08 | $31.21M derived: sum of 3 quarters · filed 2025-05-08 | $31.21M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $951.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $951.00K derived: sum of 2 quarters · filed 2025-03-18 | $951.00K derived: sum of 3 quarters · filed 2025-03-18 | $9.93M 10-K · filed 2025-03-18 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $8.98M 10-Q · filed 2024-11-06 | $74.17M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $8.98M 10-Q · filed 2024-08-08 | $74.17M derived: sum of 3 quarters · filed 2024-08-08 | $80.98M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $8.98M 10-Q · filed 2024-05-07 | $74.17M derived: sum of 2 quarters · filed 2024-05-07 | $80.98M derived: sum of 3 quarters · filed 2024-05-07 | |
| 2022-12-31 | $65.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $72.00M derived: sum of 2 quarters · filed 2024-03-20 | $126.22M 10-K · filed 2024-03-20 | |
| 2022-09-30 | $6.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $61.02M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $54.22M 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |